Structure and function of apolipoprotein A-I and high-density lipoprotein

Current Opinion in Lipidology

Volumn 11, Issue 2, 2000, Pages 105-115

  Segrest, Jere P ^a,b,e   Li, Ling ^a   Anantharamaiah, G M ^a,b   Harvey, Stephen C ^b   Liadaki, Kalliopi N ^c   Zannis, Vassilis ^c,d  

^a Center for Palliative Care   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF CRETE   (Greece)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

HUMAN; LIPID TRANSPORT; MOLECULAR BIOLOGY; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 0034089149     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200004000-00002     Document Type: Review

References (78)

1. 1 Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8:737-741.
2. 2 Segrest JP, Anantharamaiah GM. Pathogenesis of atherosclerosis. Curr Opin Cardiol 1994; 9:404-410.
3. 3 Segrest JP, Jackson RL, Morrisett JD, Gotto Jr AM. A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS Lett 1974; 38:247-253.
4. 4 Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992; 33:141-166.
5. 5 McLachlin AD. Repeated helical pattern in apolipoprotein A-I. Nature 1977; 267:465-466.
6. 6 Karathanasis SK, Zannis VI, Breslow JL. Isolation and characterization of the human apolipoprotein A-I gene. Proc Natl Acad Sci USA 1983; 80:6147-6151.
7. 7 Nolte RT, Atkinson D. Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys J 1992; 63:1221-1239.
8. 8 Palgunachari MN, Mishra VK, Lund-Katz S, Phillips MC, Adeyeye SO Alluri S, et al. Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly. Arterioscler Thromb Vasc Biol 1996; 16:328-338.
9. 9 Rogers DP, Roberts LM, Lebowitz J, Engler JA, Brouillette CG. Structural analysis of apolipoprotein A-I: effects of amino- and carboxy-terminal deletions on the lipid-free structure. Biochemistry 1998; 37:945-955.
10. 10 Gursky O, Atkinson D. Thermal unfolding of human high-density apolipoprotein A-I: implications for a lipid-free molten globular state. Proc Natl Acad Sci USA 1996; 93:2991-2995.
11. 11 Davidson WS, Arnvig-McGuire K, Kennedy A, Kosman J, Hazlett TL, Jonas A. Structural organization of the N-terminal domain of apolipoprotein A-I: studies of tryptophan mutants. Biochemistry 1999; 38:14387-14395.
12. 12 Borhani DW, Rogers DP, Engler JA, Brouillette CG. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 1997; 94:12291-12296.
13. 13 Rogers DP, Brouillette CG, Engler JA, Tendian SW, Roberts L, Mishra VK, et al. Truncation of the amino terminus of human apolipoprotein A-I substantially alters only the lipid-free conformation. Biochemistry 1997; 36:288-300.
14. 14 Wlodawer A, Segrest JP, Chung BH, Chiovetti Jr R, Weinstein JN. High-density lipoprotein recombinants: evidence for a bicycle tire micelle structure obtained by neutron scattering and electron microscopy. FEBS Lett 1979; 104:231-235.
15. 15 Atkinson D, Small DM, Shipley GG. X-ray and neutron scattering studies of plasma lipoproteins. Ann N Y Acad Sci 1980; 348:284-298.
16. 16 Segrest JP, Jones MK, Klon AE, Sheldahl CJ, Hellinger M, De Loof H, et al. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J Biol Chem 1999; 274:31755-31758. A detailed model for the lipid-associated carboxyl-terminal domain of apolipoprotein A-I is constructed based upon the assumption that lipid imposes profound constraints on the conformation and orientation of proteins associated with it. In the model, two apolipoprotein A-I molecules are wrapped belt-wise around a small discoidal patch of bilayer containing 160 lipid molecules. A striking 11mer/22mer periodicity in perfectly aligned interhelical salt bridges was found. The structure with the most favorable alignment of salt bridges exactly matches that of the (nonplanar) crystal structure of lipid-free apolipoprotein A-I.
17. 17 Segrest JP. Amphipathic helixes and plasma lipoproteins: thermodynamic and geometric considerations. Chem Phys Lipids 1977; 18:7-22.
18. 18 Tall AR, Small DM, Deckelbaum RJ, Shipley GG. Structure and thermodynamic properties of high density lipoprotein recombinants. J Biol Chem 1977; 252:4701-4711.
19. 19 Phillips JC, Wriggers W, Li Z, Jonas A, Schulten K. Predicting the structure of apolipoprotein A-I in reconstituted high-density lipoprotein disks. Biophys J 1997; 73:2337-2346.
20. 20 Jones MK, Anantharamaiah GM, Segrest JP. Computer programs to identify and classify amphipathic alpha helical domains. J Lipid Res 1992; 33:287-296.
21. 21 Koppaka V, Silvestro L, Engler JA, Brouillette CG, Axelsen PH. The structure of human lipoprotein A-I. Evidence for the 'belt' model. J Biol Chem 1999; 274:14541-14544. This study of discoidal HDL using a novel form of polarized internal reflection infrared spectroscopy under native conditions provides unambiguous support for the belt model.
22. 22 Cheung MC, Segrest JP, Albers JJ, Cone JT, Brouillette CG, Chung BH, et al. Characterization of high density lipoprotein subspecies: structural studies by single vertical spin ultracentrifugation and immunoaffinity chromatography. J Lipid Res 1987; 28:913-929.
23. 23 Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665:408-419.
24. 24 Zambon A, Hokanson JE. Lipoprotein classes and coronary disease regression. Curr Opin Lipidol 1998; 9:329-336. This paper reviews the current state of knowledge of the role of lipoprotein classes and subclasses in cause and reversal of coronary artery disease.
25. 25 Mishra VK, Palgunachari MN, Datta G, Phillips MC, Lund-Katz S, Adeyeye SO, et al. Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic alpha-helixes. Biochemistry 1998; 37:10313-10324.
26. 26 Rogers DP, Roberts LM, Lebowitz J, Datta G, Anantharamaiah GM, Engler JA, Brouillette CG. The lipid-free structure of apolipoprotein A-I: effects of amino-terminal deletions. Biochemistry 1998; 37:11714-11725.
27. 27 Laccotripe M, Makrides SC, Jonas A, Zannis VI. The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein. J Biol Chem 1997; 272:17511-17522.
28. 28 von Eckardstein A, Funke H, Walter M, Altland K, Benninghoven A, Assmann G. Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are non-randomly distributed throughout the apolipoprotein A-I primary structure. J Biol Chem 1990; 265:8610-8617.
29. 29 Zannis VI, Kardassis D, Zanni EE. Genetic mutations affecting human lipoproteins, their receptors, and their enzymes. In: Advances in Human Genetics, vol 21. Harris H, Hirschorn K (editors). New York, NY: Plenum Publishing Corporation; 1993:145-319.
30. 30 Forte TM, Goth-Goldstein R, Nordhausen RW, McCall MR. Apolipoprotein A-I-cell membrane interaction: extracellular assembly of heterogeneous nascent HDL particles. J Lipid Res 1993; 34:317-324.
31. 31 Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36:211-228.
32. 32 von Eckardstein A, Huang Y, Assmann G. Psysiological role and clinical relevance of high density lipoprotein subclasses. Curr Opin Lipid 1994; 5:404-416.
33. 33 Francone OL, Gurakar A, Fielding C. Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem 1989; 264:7066-7072.
34. 34 Durbin DM, Jonas A. Lipid-free apolipoproteins A-I and A-II promote remodeling of reconstituted high density lipoproteins and alter their reactivity with lecithin:cholesterol acyltransferase. J Lipid Res 1999; 40:2293-2302. Recornbinant HDLs containing apolipoprotein A-I or apolipoprotein A-II interact at 37 C and exchange with free apoproteins as determined by fluorescence polarization. Replacement of apolipoprotein A-I by A-II reduces the LCAT activation ability of the remodeled recombinant HDL particles.
35. 1 particles containing apolipoprotein A-I and phospholipid.
36. 36 Gillotte KL, Davidson WS, Lund-Katz S, Rothblat GH, Phillips MC. Removal of cellular cholesterol by pre-beta-HDL involves plasma membrane microsolubilization. J Lipid Res 1998; 39:1918-1928.
37. 37 Handwerger S, Datta G, Richardson B, Schmidt CM, Siddiqi T, Turzai L, Anantharamaiah GM. Pre-beta-HDL stimulates placental lactogen release from human trophoblast cells. Am J Physiol 1999; 276:E384-E389.
38. 38 Francis GA, Knopp RH, Qram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Invest 1995; 96:78-87.
39. 39 Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet 1999; 22:336-345. Mutations in ABC1 were detected in both Tangier disease and familial HDL deficiency, indicating that the two are allelic. The authors suggest that the protein encoded by ABC1 is a key element in influencing intracellular cholesterol transport.
40. 40 Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-51. Five kindreds with Tangier disease were analyzed and seven different mutations were found, suggesting that Tangier disease is caused by mutations in ABC1 located on chromosome 9q22-31.
41. 41 Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet 1999; 22:352-355. The full-length complementary DNA for ABC1 was cloned and the gene in two unrelated families with four Tangier disease homozygotes was sequenced. The results support the concept that defects in ABC1 are the cause of Tangier disease.
42. 42 Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci USA 1999; 96:12685-12690. A report of the organization of the human ABC1 gene and the identification of a mutation in the ABC1 gene from the original Tangier disease kindred.
43. 43 Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25-R31. The ABC1 transporter was identified as the defect in Tangier disease by a combined strategy of gene expression microarray analysis, genetic mapping, and biochemical studies.
44. 44 Luciani MF, Denizot F, Savary S, Mattei MG, Chimini G. Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 1994; 21:150-159.
45. 45 Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 1999; 257:29-33. This observation that ABC1 expression is upregulated by increased cholesterol in macrophages was the initial evidence that ABC1 participates in cellular cholesterol efflux.
46. 46 Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH. Yu L, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354:1341-146. Three French-Canadian families and one Dutch family with familial HDL deficiency were studied. A different mutation was detected in ABC1 in each family. Each mutation either created a stop codon predicted to result in truncation of ABC1, or altered a conserved amino acid residue.
47. 47 Daum U, Leren TP, Langer C, Chirazi A, Cullen P, Haydn Pritchard P, et al. Multiple dysfunctions of two apoA-I variants apoA-I (R160L) Oslo and apoA-I(P165R) that are associated with hypoalphalipoproteinemia in heterozygous carriers. J Lipid Res 1999; 40:486-494.
48. 48 Sorci-Thomas M, Kearns MW, Lee JP. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltransferase activation. J Biol Chem 1993; 268:21403-21409.
49. 49 Frank PG, N'Guyen D, Franklin V, Neville T, Desforges M, Rassart E, et al. Importance of central x-helices of human apolipoprotein A-I in the maturation of high density lipoproteins. Biochemistry 1998; 37:13902-13909. Apolipoprotein A-I mutants with deletion of helices 4,5, 5,6, and 6,7 have no effect on cholesterol efflux. A deletion mutant that lacks helices 6,7 reduced LCAT activation, cholesteryl ester acceptance from LDL, and phospholipid association.
50. 50 Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW, Landrum M. The hydrophobic face orientation of apolipoprotein A-I amphipathic helix domain 6 143-164 regulates lecithin:cholesteryl acyltransferase activation. J Biol Chem 1998; 273:11776-11782.
51. 51 Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity. J Biol Chem 1997; 272:7278-7284.
52. 52 Dhoest A, Zhao Z, De Geest B, Deridder E, Sillen A, Engelborghs Y, et al. Role of the Arg123-Tyr166 paired helix of apolipoprotein A-I in lecithin:cholesterol acyl transferase activation. J Biol Chem 1997; 272:15967-15972.
53. 53 Peelman F, Vinaimont N, Verhee A, Vanloo B, Verschelde J-L, Labeur C, et al. A proposed architecture for lecithin cholesterol acyl transferase (LCAT): identification of the catalytic triad and molecular modeling. Protein Sci 1998; 7:587-599. A three-dimensional model for the LCAT is proposed based on structural homologies with x/β hydrolases and functional analysis of LCAT mutants.
54. 54 Sparks DL, Frank PG, Braschi S, Neville TA, Marcel YL. Effect of apolipoprotein A-I lipidation on the formation and function of pre-β and x-migrating LpA-I particles. Biochemistry 1999; 38:1727-1735. In-vitro experiments showed gradual association of phospholipid with apolipoprotein A-I leading to the formation of an unstable lipoprotein A-I particle containing one apolipoprotein A-I molecule, which is an efficient substrate for LCAT. The interaction of lipoprotein A-I with LCAT suggests direct apolipoprotein A-I-LCAT interactions.
55. 55 Stein O, Stein Y. The removal of cholesterol from Landschutz ascites cells by high-density apolipoprotein. Biochim Biophys Acta 1973; 326:232-244.
56. 56 Rothblat GH, Mahlberg FH, Johnson WJ, Phillips MC. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J Lipid Res 1992; 33:1091-1097.
57. 57 Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 1999; 40:187-201. A comprehensive review of numerous HDL-binding proteins and receptors is presented.
58. 58 Burgess JW, Frank PG, Franklin V, Liang P, McManus DC, Desforges M, et al. Deletion of the C-terminal domain of apolipoprotein A-I impairs cell surface binding and lipid efflux in macrophage. Biochemistry 1999; 38:14524-14533. Deletion of helixes 8-10 of apoliporpotein A-I reduced its ability to bind to macrophages and to induce efflux of cholesterol or phospholipid from macrophages but not from fibroblasts.
59. 59 Krieger M. Charting the fate of the 'good cholesterol': Identification and characterization of the high-density lipoprotein receptor SR-BI. Ann Rev Biochem 1999; 68:523-558. A comprehensive review of SR-BI is provided. Specific functions of SR-BI in HDL-cholesterol levels and the pathogenesis of atherosclerosis are established in [60•-62•].
60. 60 Arai T, Wang N, Bezouevski M, Welch C, Tall AR. Decreased atherosclerosis in heterozygous lowdensity lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 1999; 274:2366-2371. See [59••].
61. 61 Ueda Y, Royer L, Gong E, Zhang J, Cooper PN, Francone O, Rubin EM. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem 1999; 274:7165-7171. See [59••).
62. 62 Trigarti B, Rayburn H, Vinals M, Braun A, Miettinen H, Penman M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 1999; 96:9322-9327. See [59••).
63. 63 Xu S, Laccotripe M, Huang X, Rigotti A, Zannis VI, Krieger M. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res 1997; 38:1289-1298.
64. 64 Rodrigueza WV, Thuahnai ST, Temel RE, Lund-Katz S, Phillips MC, Williams DL. Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. J Biol Chem 1999; 274:20344-20350.
65. 65 Liadaki KN, Ishida BY, Xu S, Kane J, Zannis VI, Krieger M. Association with lipids and the C- and N-terminal domains of apoA-I influence its binding to the HDL receptor SR-BI. Circulation 1999; 100(18):684.-
66. 66 Moestrup SK, Kozyraki R, Kristiansen M, Kaysen JH, Rasmussen HH, Brault D, et al. The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J Biol Chem 1998; 273:5235-5242. This paper establishes that cubulin receptor binds and internalizes HDL.
67. 67 Hammad SM, Stefansson S, Twal WO, Drake CJ, Fleming P, Remaley A. Cubulin, the endocytic receptor for intrinsic factor-vitamin B12 complex, mediates HDL holoparticle endocytosis. Proc Natl Acad Sci USA 1999; 96:10158-10163. Cubulin-HDL interactions lead to renal clearance of apolipropotein A-I and small size HDL and may provide maternal HDL to the embryo.
68. 68 Albers JJ, Pitman W, Wolfbauer G, Cheung MC, Kennedy H, Tu AY, et al. Relationship between phospholipid transfer protein activity and HDL level and size among inbred mouse strains. J Lipid Res 1999; 40:295-301. This study of 15 inbred mouse strains showed that phospholipid transfer protein is highly correlated with plasma phospholipid, HDL phospholipid, HDL-cholesterol, and the percentage of large HDL particles.
69. 69 Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103:907-914. This study demonstrated that phospholipid transfer protein is the major factor facilitating transfer of VLDL phospholipid into HDL, and that a transfer of surface components of triglyceride-rich lipoproteins is important in the maintenance of HDL levels.
70. 70 Chung BH, Tallis G, Yalamoori V, Anantharamaiah GM, Segrest JP. Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally simitar to surface remnants of triglyceride-rich lipoproteins. Arterioscler Thromb 1994; 14:622-635.
71. 71 Pussinen PJ, Jauhiainen M, Metso J, Pyle LE, Marcel YL, Fidge NH, Ehnholm C. Binding of phospholipid transfer protein (PLTP) to apolipoproteins and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I. J Lipid Res 1998; 39:152-161. Physical Interactions between phospholipid transfer protein and the amino terminal domain of apolipoprotein A-I have been demonstrated using solid-phase ligand-binding assay and apolipoprotein A-I and apolipoprotein A-II affinity chromatography. The domain of apolipoprotein A-I required for PL binding is in the vicinity of residues 27-48.
72. 72 Grundy SM, Vega GL, Otvos JD, Rainwater DL, Cohen JC. Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men. Genetic and pharmacological evidence. J Lipid Res 1999; 40:229-234. HDL subclass distributions were compared as a function of hepatic lipase isotypes and levels in humans. The resulting genetic and pharmacological data suggested that variation in hepatic lipase activity has highly specific effects on the distribution of HDL subclasses in the circulation.
73. 3.
74. 74 Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nature Genet 1999; 21:424-428. This paper describes the cloning and expression in transgenic mice of a new lipase family member, which is normally expressed in endothelial cells and other tissues.
75. 75 Silver DL, Jiang XC, Tall AR. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ ob mice. Possible role of leptin in stimulation of HDL turnover. J Biol Chem 1999; 274:4140-4146. This study in ob/ob mice suggests that a specific HDL particle catabolic pathway is downregulated in ob/ob mice and that HDL apolipoprotein turnover may be regulated by obesity or leptin signaling.
76. 76 Hosoai H, Webb NR, Glick JM, Tietge UJ, Purdom MS, de Beer, FC, Rader DJ. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res 1999; 40:648-653. This recent study showed that high plasma levels of SAA in the absence of a generalized acute-phase response does not result in reduction of HDL-cholesterol or apolipoprotein A-I.
77. 77 Cabana VG, Reardon CA, Wei B, Lukens JR, Getz GS. SAA-only HDL formed during the acute phase response in apoA-I+/+ and apoA-I -/- mice. J Lipid Res 1999; 40:1090-1103. SAA forms dense but large HDL particles independently of the availability of apolipoprotein A-I or other apolipoproteins.
78. 78 Hajn T, Elliott-Bryant R, Sipe JD, Liang JS, Hayes KC, Cathcart ES. The acute phase response in apolipoprotein A-1 knockout mice: apolipoprotein serum amyloid A and lipid distribution in plasma high density lipoproteins. Biochim Biophys Acta 1998; 1394:209-218. Apolipoprotein AI-rich HDL particles are not necessary for SAA transport in the plasma.